Key result
A novel purpose-built containment facility, Poliopolis, was created to study new monovalent OPV2 vaccine candidates in healthy adult volunteers under strict containment provisions.
Why the study?
Global withdrawal of live attenuated type 2 Sabin poliovirus created containment challenges for developing and testing novel type 2 poliovirus vaccines.
Describes the creation of Poliopolis, a purpose-built containment facility for testing novel type 2 poliovirus vaccines.
Answers are grounded in this paper and cite their sources.
Provides contained infrastructure for OPV2 candidate testing; extends research capacity for polio eradication studies without practice implications.
Although global polio eradication is within reach, sustained eradication of all polioviruses requires cessation of oral poliovirus vaccine use to mitigate against vaccine-derived poliovirus circulation and vaccine-associated paralytic poliomyelitis. The first step in this direction was the WHO-recommended global withdrawal of live attenuated type 2 Sabin poliovirus from routine immunisation in May 2016, with future use restricted to outbreak response, and handling controlled by strict containment provisions (GAPIII). This creates unique challenges for development and testing of novel type 2 poliovirus vaccines. We describe the creation of a novel purpose-built containment facility, Poliopolis, to study new monovalent OPV2 vaccine candidates in healthy adult volunteers, which may be a model for future endeavors in vaccine development for emergency use.
No takes yet. Share an insight, caveat, or question.
Damme et al. (2019) studied Polio. Poliopolis containment facility was evaluated. A novel purpose-built containment facility, Poliopolis, was created to study new monovalent OPV2 vaccine candidates in healthy adult volunteers under strict containment provisions.
Synapse has enriched 10 related papers. Consider them for comparative context: